What move does the options market price into Enliven Therapeutics's report?

Implied ±8.0%, either direction.

How often does Enliven Therapeutics move more than the options market prices?

0 of the last 8 reports moved at least as far as the implied move.

ELVNNasdaqPharmaceutical Preparations

Enliven Therapeutics, Inc. (ELVN) earnings date, market-implied expected move, and options open interest by expiry

44.80

Pre-market16:00 ETdelayed

Open45.83Volume2.1MMkt cap$3.3BEPS-1.64

Day44.79 – 45.830%52-wk14.79 – 62.3263%

ELVN

Enliven Therapeutics, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

Inputs

±8.0%implied · report alone

8Q avg ±3.0%·×2.71·rich

41.2348.43

straddle ±10.8%

spot 44.83exp Nov 20ATM strike 45ATM straddle 5.70IV 74%

Nov 3 closereport share · term structurethin chain

Expected move

Inputs

Next report

Nov 11

after close · in 7 days

est.Q3 FY26

Calendar

Next report

Last report

+0.95%

vs ±11.2% implied · ×0.08

shaded = implied · ▲▼ = realized

Aug 5 '26 · confirmed

Implied vs realized

Largest filed tie

—

Supply chain

13F top-10 QoQ

+25.71%

shares held · 10 largest managers

13F · Jun 30 '26127d lag

212 managers

Top fund weight

0.07%

ELVN weight · IWM

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Enliven Therapeutics (ELVN) is expected to report on Nov 11 after close (estimated date).

Implied vs realized

8 reports

0 of 8≥ implied

avg implied: ±16.9%
avg realized: ±3.0%

Nov 13 '24Nov 13 '24confirmed±16.6%▼−3.41%×0.21

Mar 13 '25Mar 13 '25confirmed±20.8%▲+2.22%×0.11

May 14 '25May 14 '25confirmed±19.0%▼−10.41%×0.55

Aug 13 '25Aug 13 '25confirmed±21.6%▼−1.08%×0.05

Q3 FY25Nov 12 '25confirmed±19.4%▼−0.15%×0.01

Q1 FY26Mar 3 '26confirmed±15.4%▲+4.28%×0.28

May 7 '26May 7 '26confirmed±11.1%▲+1.14%×0.10

Q2 FY26Aug 5 '26confirmed±11.2%▲+0.95%×0.08

quarterimplied−25%0+25%realized×

Q2 FY26±11.2%▲+0.95%×0.08

May '26±11.1%

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 4 expiries · Oct 28 close

0.13OI · 4 expiries · Oct 28 closeP/C open interest · Nov 20 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

420%Nov 2016d325+98%

9480%Dec 1844d1.34705−4%1.34

5570%Jan 1572d1.05528+1%1.05

750%Mar 19135d0.107860%0.10

ExpiryPutsCallsP/C

Nov 2016d420%325+98%0.13

Dec 1844d9480%705−4%1.34

Jan 1572d5570%528+1%1.05

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

scenario · straddle±10.8%

Funds 3

IWM±0.0%

UWM±0.0%

VTI±0.0%

Dashed = straddleMethod Source: SEC filings · N-PORT · market data

Linked exposure

Revenue flow

No filed income statement.

Revenue flow

Intraday

15m bars

Long dash = implied range · Nov 3 close · Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:00 ET

Intraday

Event sensitivity

FOMC ×1.24· ±4.1% vs ±3.3% · 24 releases

eventrelease day|move|up · n×base

FOMCrate decision±4.1%11 of 24×1.24

Enliven Therapeutics, Inc. (ELVN) earnings date, market-implied expected move, and options open interest by expiry

Implied vs realized

Implied vs realized

Positioning

Positioning

Linked exposure

Linked exposure

Revenue flow

Revenue flow

Intraday

Intraday

Event sensitivity

Enliven Therapeutics, Inc. (ELVN) earnings date, market-implied expected move, and options open interest by expiry

Implied vs realized

Positioning

Event sensitivity

Earnings history

Methodology

Revenue flow

Intraday

Linked exposure

Quarter	Reported	EPS	Consensus
Q2 FY26	Aug 5 '26 · confirmed	-0.49	—
Q1 FY26	Mar 3 '26 · confirmed	-0.38	—
Q3 FY25	Nov 12 '25 · confirmed	-0.32	—